Oncotarget

Research Papers:

Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent

Monika Toma _, Monika Witusik-Perkowska, Marzena Szwed, Robert Stawski, Janusz Szemraj, Malgorzata Drzewiecka, Margaret Nieborowska-Skorska, Maciej Radek, Pawel Kolasa, Ksenia Matlawska-Wasowska, Tomasz Sliwinski and Tomasz Skorski

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:36867-36877. https://doi.org/10.18632/oncotarget.26409

Metrics: PDF 633 views  |   HTML 1025 views  |   ?  


Abstract

Monika Toma1, Monika Witusik-Perkowska2, Marzena Szwed3, Robert Stawski4, Janusz Szemraj2, Malgorzata Drzewiecka1, Margaret Nieborowska-Skorska5, Maciej Radek6, Pawel Kolasa7,8, Ksenia Matlawska-Wasowska9, Tomasz Sliwinski1 and Tomasz Skorski5

1Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland

2Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland

3Department of Medical Biophysics, University of Lodz, Lodz, Poland

4Department of Clinical Physiology, Medical University of Lodz, Lodz, Poland

5Department of Microbiology and Immunology, Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA

6Department of Neurosurgery, Surgery of Spine and Peripheral Nerves, Medical University of Lodz, University Hospital WAM-CSW, Lodz, Poland

7Department of Neurosurgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

8Social Sciences Academy in Lodz, Lodz, Poland

9Division of Pediatric Research, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, NM, USA

Correspondence to:

Tomasz Sliwinski, email: tomasz.sliwinski@biol.uni.lodz.pl

Tomasz Skorski, email: tskorski@temple.edu

Keywords: glioblastoma; PARP inhibitor; LIG4; alkylating agent; synthetic lethality

Received: June 30, 2018     Accepted: November 16, 2018     Published: December 07, 2018

ABSTRACT

Cancer cells often accumulate spontaneous and treatment-induced DNA damage i.e. potentially lethal DNA double strand breaks (DSBs). Targeting DSB repair mechanisms with specific inhibitors could potentially sensitize cancer cells to the toxic effect of DSBs. Current treatment for glioblastoma includes tumor resection followed by radiotherapy and/or temozolomide (TMZ) – an alkylating agent inducing DNA damage. We hypothesize that combination of PARP inhibitor (PARPi) with TMZ in glioblastoma cells displaying downregulation of DSB repair genes could trigger synthetic lethality. In our study, we observed that PARP inhibitor (BMN673) was able to specifically sensitize DNA ligase 4 (LIG4)-deprived glioblastoma cells to TMZ while normal astrocytes were not affected. LIG4 downregulation resulting in low effectiveness of DNA-PK–mediated non-homologous end-joining (D-NHEJ), which in combination with BMN673 and TMZ resulted in accumulation of lethal DSBs and specific eradication of glioblastoma cells. Restoration of the LIG4 expression caused loss of sensitivity to BMN673+TMZ. In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26409